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Abstract
A major bottleneck in structural, biochemical and biophysical studies of proteins is the need for large amounts of pure
homogenous material, which is generally obtained by recombinant overexpression. Here we introduce a vector collection,
the pCri System, for cytoplasmic and periplasmic/extracellular expression of heterologous proteins that allows the
simultaneous assessment of prokaryotic and eukaryotic host cells (Escherichia coli, Bacillus subtilis, and Pichia pastoris). By
using a single polymerase chain reaction product, genes of interest can be directionally cloned in all vectors within four
different rare restriction sites at the 59end and multiple cloning sites at the 39end. In this way, a number of different fusion
tags but also signal peptides can be incorporated at the N- and C-terminus of proteins, facilitating their expression,
solubility and subsequent detection and purification. Fusion tags can be efficiently removed by treatment with site-specific
peptidases, such as tobacco etch virus proteinase, thrombin, or sentrin specific peptidase 1, which leave only a few extra
residues at the N-terminus of the protein. The combination of different expression systems in concert with the cloning
approach in vectors that can fuse various tags makes the pCri System a valuable tool for high throughput studies.
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Introduction
Researchers performing biochemical, biophysical and biological
studies on proteins commonly require large amounts of pure
homogeneous material, which cannot usually be purified from
natural sources. Alternatively, proteins are over-expressed heter-
ologously in various systems incorporating host cells of bacterial,
yeast, insect, or mammalian origin [1–3]. A critical step in protein
production, after target selection, is to examine as many
parameters as possible and to identify the most promising strategy
for protein expression and purification with a minimum of
resources and time.
Prior information on the protein of interest is crucial. An
extensive search in databases such as NCBI (http://www.ncbi.
nlm.nih.gov), UniProt (http://www.uniprot.org) and PDB (http://
www.pdb.org) for known homologous proteins may identify
possible problems and appropriate solutions for subsequent
experiments. In addition, it is advisable to test protein orthologs
of different origin, including distantly related or unrelated species
(bacteria, archaea, and eukaryotes). At this point, analysis of the
primary and secondary structure of both the encoding mRNA and
the translated polypeptide may anticipate downstream problems.
There is a plethora of freely available software and databases for
identifying protein families and sequence conservation patterns
(PFAM) [4], putative signal peptides (SPs; SignalIP) [5], lipoboxes
(DOLOP) [6], glycosylation, phosphorylation and other posttrans-
lational modifications [7], transmembrane domains (TOPCONS,
TMHMM, BOCTOPUS) [8–10], and unfolded/disordered
regions (DisEMBL, PONDR, PSIPRED Protein Sequence Anal-
ysis Workbench) [11–13]. Protein location within the cell, i.e.
cytoplasmic, periplasmic, or extracellular (PSORT, http://psort.
hgc.jp), provides an indication of the requirements of the protein
for proper folding, including disulfide bond formation and the
need for special chaperons in each cellular compartment [14–16].
Further prediction of the secondary structure content (JPRED,
LOMETS) [17,18] can give clues about possible protein domains
and motifs, a characterisation which may prove useful for
chopping full-length multi-domain proteins into globular moieties.
In general, successful recombinant protein expression depends on
the removal of wild-type SP, lipoboxes, posttranslational signals,
low-complexity regions, hydrophobic residues at the protein
termini and membrane spanning regions, while conserving the
boundaries of globular domains [19].
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In parallel, cDNA characterisation is important in designing the
cloning strategy and identifying potential problems at the
transcriptional and translational levels. Although these processes
are affected by a number of exo- and endo-nucleases, the stability
of the resulting mRNA is critical in protein expression experiments
[20]. mRNA can be protected by introducing sequences at the 59
untranslated regions (UTRs) and stem loop structures at the 39
UTRs [21]. The GC base content (.70%) may affect levels of
expression and can be easily determined by sequence analysis
software. Rare codons (GCUA 2.0) [22], especially consecutive
ones, are frequently found in heterologous genes and may lead to
translational errors due to ribosomal stalling [23,24]. Such codon
bias can be remedied by replacing selected codons or, if necessary,
by overall gene optimisation using appropriate software (OPTI-
MIZER) [25]. Once the above requirements are fulfilled, the gene
can be inserted into the vector by directional cloning using
restriction enzymes that do not cut within the gene sequence
(NEBcutter) [26]. Efficiency of translation termination can be
increased by introducing strong stop codons (UAA, especially in
context when followed by a U base, or consecutive ones) at the end
of the translated gene [27]. Although present in many expression
vectors, transcription terminators can be included downstream of
the transcribed gene if instability is predicted [28]. Finally, sources
of cDNA can be found in the Mammalian Gene Collection
(http://mgc.nci.nih.gov/) and at the home page of Culture
Collection of the World (http://www.ecotao.com/holism/agric/
hpcc.html).
No expression system is generic for all target proteins, so both
bacterial and eukaryotic systems need to be explored. Escherichia
coli provides the cheapest expression host, and it is the most widely
used but its machinery is not as sophisticated as that of eukaryotic
hosts, and it cannot always express well folded proteins of variable
origin [15]. Other alternatives often need to be tested, including
bacterial systems such as Bacillus subtilis [29] and more advanced
eukaryotic systems such as the yeasts Pichia pastoris [1] and
Saccharomyces cerevisiae [30], the baculovirus expression system in
insect cells [3], mammalian cells [31], or cell-free systems using
prokaryotic extracts [32], which have highly variable cost-
efficiency ratios.
With E. coli alone, many variables can be tested in order to
improve expression levels and achieve proper protein folding
[2,33]. A number of specialised strains carrying mutations [34,35]
or plasmids that co-express proteins favouring expression at the
transcriptional or translational level (e.g. pRARE or pLysE/
pLysS) are available [24,36]. Coupled expression of exogenous
chaperones can assist in proper folding and prevent protein
aggregation [37,38]. Expression can also be influenced by other
parameters, such as the culture method (e.g. batch fermentation,
fed batch and dialysis fermentation) [39], cell growth media
composition (lysogeny broth (LB), the enriched terrific broth (TB),
two times yeast and tryptone broth (26YT), and auto-induction
media) [40], and culture conditions like temperature (18–37uC),
shaking, aeration and other physical variables. All these factors can
affect production levels, secretion, protein folding, solubility and
host proteolytic activity [41,42].
The many systems for introducing fusion tags currently
available were originally developed to facilitate the detection and
purification of recombinant proteins. Tags such as polyhistidine
(His6-tag) and streptavidin-binding peptide (Strep-tag) allow
purification by affinity chromatography and protein detection by
Western blotting [43,44], and others such as C-terminally fused
green fluorescent protein (GFP) are an indispensable tool for
membrane protein biochemists [45]. Finally, several studies have
shown that the introduction of tags at the N- or C-terminus of
proteins can improve expression levels by providing an optimized
environment for translation initiation and mRNA protection,
protein solubility [46–48], and carrier-driven crystallisation
experiments [49].
Here we present a collection of vectors with which various
expression systems and fusion tags can be evaluated simply and
effectively. We examine the applicability of this system and
provide several test cases, which support its robustness and
versatility. This vector collection, which has been extensively
tested and modified, is freely available to the scientific community
under Addgene (https://www.addgene.org).
Materials and Methods
Genetic manipulations and vector preparation
Three series of vectors were generated on the basis of vectors
available from the European Molecular Biology Laboratory
(pETMBP-1a, pETTRX-1a, and pETGST), Novagen (pET-26b,
and pET-28a), MoBiTec (pHT-01, and pHT-43), Invitrogen
(pPICZA and pPICZaA), and from the Glockshuber laboratory
(pRBI-DsbC) [50]. The inserted sequences for pCri-11, 13, and 14
were amplified from pET-15b-SUMO1 [51], pMIS3.0E [52], and
pKLSLt [53], respectively. All vectors were prepared for
directional cloning in NcoI or NdeI restriction sites at the 59end
and in XhoI at the 39end. The gene coding for GFP (UniProt code:
B6UPG7; 729 bp), including a multiple cloning site (MCS; from
pETMBP-1a; 52 bp), was introduced into all vectors. The insert
was cloned between the NcoI or NdeI and XhoI restriction sites
and was modified to contain an MscI or NheI restriction site
immediately after the NcoI and NdeI sites, respectively. Standard
cloning techniques were used throughout [54]. Polymerase chain
reaction (PCR) primers and DNA modifying enzymes were
purchased from Sigma-Aldrich and Thermo-Scientific, respective-
ly. PCR was performed using Phusion high-fidelity DNA
polymerase (Thermo-Scientific) according to the manufacturer’s
instructions and following a standard optimisation step of a
thermal gradient in each reaction. For vector preparation, a
number of insertions and mutations introduced or eliminated
nucleotide sequences. We followed a PCR-based strategy
described elsewhere [55], including a DpnI digestion step to
remove parental DNA. Digestion with restriction enzymes was
carried out according to standard protocols. When necessary, a
second round of digestion was performed before the final DNA
purification step. DNA was purified from PCR reactions,
enzymatic reactions, agarose gel band extractions, and vector
extractions using OMEGA-Biotek purification kits. Chemically
competent E. coli DH5a, BL21 (DE3), and Origami 2 (DE3) cells
(Novagen) were prepared and transformed following Hanahan
method [56]. Competent cells of P. pastoris KM71H (Invitrogen)
and B. subtilis WB800N (MoBiTec) were prepared according to
the manufacturer’s instructions.
Protein expression and purification
For expression trials, mecR1 (UniProt code: P0A0B0; an
integral-membrane metallopeptidase) was cloned into vector
pCri-8a and 13a; the gene coding for fragilysin (UniProt code:
O86049; Ala212-Asp397; a soluble metalloendopeptidase) into
pCri-1a, 4a, 6a and 8a; gfp into pCri-1a, 4a, 6a, 8a, 11a, and 14a;
the gene coding for carboxypeptidase A2 (CPA2; UniProt code:
P48052; Leu19-Tyr419; a soluble metalloexopeptidase) into pCri-
8a, 9a, 16a, and 18a; and the gene coding for peptide-N-
glycosidase F (PNGase F; UniProt code: P21163; Ala41-Asp354; a
soluble glycosidase) into pCri-4a and 8a. The constructs were
transformed in E. coli BL21 (DE3), Origami 2 (DE3), or B. subtilis
pCri System
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cells and plated on LB plates supplemented with antibiotics
(30 mg/mL kanamycin or 5 mg/mL chloramphenicol). A single
colony was inoculated in 5 mL LB broth and incubated overnight
at 30uC with stirring at 250 rpm. 1 mL of the pre-inoculum was
used to inoculate 100 mL of LB broth and cells were left to grow at
37uC until OD600 nm<0.7–0.8. Subsequently, cells were incubated
with 0.4–1 mM isopropyl-b-D-1-thiogalactopyranoside (IPTG) to
induce protein expression and kept for 5 h at 37uC or overnight at
20uC.
For expression trials in P. pastoris cells, vectors were linearized
with PmeI restriction enzyme and transformed using the Pichia
EasyComp transformation kit (Invitrogen). Cells were inoculated
in low salt yeast peptone dextrose (YPD) plates supplemented with
100 mg/mL zeocin and incubated for 3–4 days at 28uC. Colonies
were selected and grown in 100 mL buffered complex glycerol
medium (BMGY) at 28uC until an OD600 nm<2. Cells were then
harvested, resuspended in buffered complex methanol medium
(BMMY), and protein expression was induced with 0.5%
methanol.
Cells were separated from the growth media by centrifugation
at 8,0006g for 30 min at 4uC. Secreted proteins were collected
from the growth media and dialysed in buffer A (50 mM Tris-
HCl, 250 mM NaCl, pH 7.5), and cytoplasmic proteins were
extracted from the cells in the same buffer. For lysis, cells were
sonicated with 3 pulses of 5 min each at 40% amplitude (Branson
digital sonifier). Samples were collected before and after centrifu-
gation (30,0006g for 30 min at 4uC) representing total and soluble
protein fractions, respectively.
Selected samples were further purified by affinity chromatog-
raphy using either nickel-nitrilotriacetic acid- (Ni-NTA), maltose
binding protein- (MBP) or glutathione S-transferase- (GST)
HiTrap columns, or a Sepharose 4B matrix column (GE
Healthcare Life Sciences). 10 mL of crude protein extract was
applied to the columns, followed by three washes with buffer A.
Proteins were eluted with buffer A supplemented with either
300 mM imidazole (Ni-NTA-affinity), 10 mM maltose (MBP-
affinity), 10 mM reduced glutathione (GST-affinity) or 20 mM
lactose (Sepharose-affinity). Finally, samples were buffer-ex-
changed to buffer B (20 mM Tris-HCl, 150 mM NaCl, pH 7.4)
using a PD-10 desalting column (GE Healthcare Life Sciences).
Samples were kept at 4uC at all times.
For expression and purification of MecR1, the cultures were
scaled up to 6L, the collected cells were broken with a cell
disrupter (Constant Cell Disruption Systems) at 2.4kBar and non-
disrupted cells and cell debris were removed by centrifugation at
20,0006g for 45 min in a Sorvall centrifuge. Membranes were
collected by ultracentrifugation at 150,0006g for 2 h at 4uC in a
Beckman Optima L-90K using a 50.2 Ti rotor (Beckman) and
26.3-ml polycarbonate bottles with cap assembly (Beckman).
Collected membranes were homogenized using a glass Potter and
solubilized under gentle stirring by overnight incubation at 4uC in
buffer C (50 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole,
1 mM 1,4-dithio-D-threitol, pH 8.0) containing 100 mM lauryl-
dimethylamine N-oxide (LDAO; Sigma) and EDTA-free protein-
ase inhibitor cocktail tablets (Roche). Non-solubilized proteins
were removed by ultracentrifugation as described above. The
sample was incubated overnight at 4uC with Ni-NTA resin
(Invitrogen). The bound protein was batch purified in an open
column (Bio-Rad), washed extensively, and the tagged protein
eluted with buffer C plus 300 mM imidazole. The sample was
desalted using a PD-10 column in buffer C containing 5 mM
LDAO.
Fusion-tag removal by proteinase cleavage
Tobacco etch virus (TEV) proteinase and sentrin specific
proteinase 1 (SENP1) were over-expressed in E. coli BL21 (DE3)
pLysE cells using pET28-based vectors, which attach an N-
terminal His6-tag. Cultures (typically 4L) were grown in LB broth
at 37uC until an OD600 nm<0.7–0.8, induced with 0.5 mM IPTG,
and incubated either overnight at 20uC or for 5 h at 30uC for
TEV proteinase or SENP1 expression, respectively. Subsequently,
cells were collected by centrifugation at 5,0006g for 30 min at
4uC and partially purified by Ni-NTA affinity chromatography as
previously described [57,58]. Proteinases were stored at 280uC in
buffer D (20 mM Tris-HCl, 50 mM NaCl, pH 7.5, 30% glycerol).
Proteinase cleavage trials of tagged-proteins were performed
overnight at 4uC in buffer B using various protein:proteinase
ratios. For trials with thrombin (GE Healthcare Life Sciences), 2
units of proteinase were used to process 25 mg of protein in 100 mL
of buffer C at room temperature and aliquots were taken at
various time points.
Enzymatic assays
For hydrolytic activity measurements, PNGase F and fragilysin
were partially purified by Ni-NTA-affinity chromatography as
described above. Glycosidase activity of PNGase F was tested
against the glycoprotein ribonuclease B (RNase B; New England
Biolabs) at a w/w ratio of 1:5 PNGase F/RNase B and a final
protein concentration of 0.5 mg/mL. Reactions were incubated
overnight at 4uC and analysed by SDS-PAGE. Peptidase activity
of fragilysin was tested against BODIPY FL-casein (Invitrogen) as
previously described [59]. Crude protein extracts of CPA2 were
used for assays after an initial activation with partial tryptic
digestion in a w/w ratio of 1/100 of CPA2/trypsin at room
temperature for 1 h. The activated protein was incubated with
furyl-acryloyl-L-phenylalanine-L-phenylalanine (0.05 mM; Sigma)
in buffer B and the activity was monitored by measurement of the
absorbance change at 330 nm.
Western-blot analysis
Protein samples were analyzed by Tricine-SDS-PAGE, trans-
ferred to Hybond ECL membranes (GE Healthcare Life Sciences),
and finally blocked overnight at room temperature with 20 mL of
blocking solution (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.47 mM NaH2PO4, 0.05% Tween 20) containing
1.5% bovine serum albumin. MecR1 was detected by immunoblot
analysis using custom polyclonal antibodies (Eurogentec) at
dilution 1:1,000 and a secondary antibody (goat anti-rabbit IgG
(HL) peroxidase-conjugated antibody; Pierce) at dilution 1:5,000
(both in blocking solution). The immune complexes were detected
using an enhanced chemiluminescence system (Super Signal West
Pico Chemiluminescent; Pierce) according to the manufacturer’s
instructions. Membranes were exposed to hyperfilm ECL films
(GE Healthcare Life Sciences).
Miscellaneous
Denatured protein samples were analyzed by 10%–15%
Tricine-SDS-PAGE [60] and stained with Coomassie-brilliant
blue. Protein concentrations were routinely determined by
absorbance at 280 nm, and, wherever necessary, corrected by
the BCA protein assay method (Thermo Scientific) using bovine
serum albumin as a standard. Protein identification by peptide
mass fingerprinting was performed at the Protein Chemistry
Facility of Centro de Investigaciones Biolo´gicas (Madrid, Spain).
Figures of vector maps were prepared with GENEIOUS
(Biomatters).
pCri System
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Results and Discussion
Description of the pCri System
We generated a collection of vectors for recombinant protein
overexpression in two bacterial (E. coli and B. subtilis) and one
eukaryotic (P. pastoris) host strains. Vectors, available from
commercial sources or laboratories, were initially modified by
inserting new nucleotide sequences or point mutations, and finally
evaluated for functionality. Most of the E. coli vectors are pET
based [61] with the exception of pCri-12, which is based on
pTrc99a [50]. The bacillus and yeast vectors are based on pHT
[62] and pPICZ series [63], respectively, and can be stably
propagated in E. coli cells when antibiotic resistance is conferred
(Tables 1–3). In all vectors, protein expression is achieved by
IPTG induction, except for the yeast vectors, for which methanol
is required.
The collection consists of 29 vectors grouped into three main
categories (Tables 1–3). Based on the available 59end restriction
sites for target gene cloning, the vectors are sorted into pCri-a and
pCri-b series using either NcoI and MscI or NdeI and NheI sites,
respectively (Fig. 1 and Fig. S1). The pCri-a series is further
separated into pCri-a and pCri-a-Strep based on the fusion tag
that can be attached at the C-terminus of the target protein.
Within each category, the vectors allow obtaining constructs with
different fusion tags or expression in a particular host organism.
Usage of the aforementioned 59end restriction sites incorporates a
methionine start codon, thus obviating the need to introduce it
into the target gene during PCR amplification. An MCS universal
for all vectors has been placed at the 39end, which encodes seven
rare restriction sites not found in most of the vectors (see vector
maps for more details; Fig. S1). For convenience and tracking
during vector preparation, a GFP insert is cloned within all
vectors. The inserted genes can be sequenced from either terminus
with specific primers as detailed in Table 4.
Preparation is greatly simplified, as only two restriction sites are
used for directional cloning of a target gene into a large series of
vectors. Although newer cloning techniques are now available (e.g.
ligation independent cloning system [64]), this method was
satisfactory. Cloning of target genes of variable size spanning
from 150 to 7,000 base pairs was routinely performed with a
success rate of more than seven out of ten positive clones when
genes were cloned between an NcoI or NdeI and a XhoI site. To
achieve reproducible results, it was essential to repeat double
digestions of the vectors with all the restriction enzyme combina-
tions.
Applications and main considerations of the pCri System
The choice and use of a suitable vector should be based on the
properties of the target protein and the needs of the experiment in
question. Here, in an effort to evaluate the functionality of the
collection and to provide a rationale for the use of the vectors, we
cloned and expressed several proteins of different origin and
function:
Fusion tags assisting in protein purification. The pCri
System allows the fusion of a His6–8-tag at the N-terminus of the
target protein, which can be in tandem with larger tags such MBP
[43], GST [65], small ubiquitin-like modifier (SUMO) [66], and
the b-trefoil lectin module of protein LSL150 from the mushroom
Laetiporus sulphureus (LSL) [53] (Tables 1–3). The C-terminus of
the target protein can likewise be furnished with a His6-tag or a
Strep-tag if the stop codon of the amplified gene is omitted. These
tags add a functionality to the target protein, which is commonly
used as a first purification step through affinity chromatography
[43,53,65]. On this basis, we cloned and expressed GFP in pCri-
1a, 4a, 6a, 8a, 11a, and 14a. The proteins were purified by Ni-
NTA affinity chromatography except for MBP, GST, and LSL
fusion products, which were purified by their specific affinity resins
(Fig. 2A). Nickel or cobalt affinity chromatography of His6-tagged
proteins are among the most commonly used methods for
purification, but others using the affinity properties of MBP or
GST, and the recently reported LSL150, can provide better
purification results under mild elution conditions. This choice
among alternative affinity purification systems allows the best
purification method to be used for each target protein. Moreover,
many of those tags can be used to track poorly expressed proteins
by Western-blot analysis, as they are otherwise undetectable by
Coomassie-stained SDS-PAGE.
Fusion tags assisting in protein solubility. In addition,
several studies showed that tags such as N-utilisation substrate A
(NUSA), MBP, or the smaller GST and SUMO have positive
effects on the cargo protein due to their solubility-enhancing or
chaperoning properties [2,66,67]. Nevertheless, their working
mechanism is still controversial, with several studies suggesting a
more passive role due to their excellent solubility properties rather
than a direct influence on the folding of their partner [47]. For
example, fragilysin (Ala212-Asp397) [59], a bacterial enterotoxin
metallopeptidase, was expressed in high amounts in fusion with
MBP, TRX, GST, and His6-tag, both at 37uC or 20uC (Fig. 2B).
However, only MBP rendered the protein soluble during low
temperature expression trials, whereas other fusions or expression
at higher temperatures produced protein prone to aggregation.
The protein remained in solution even after MBP removal
(Fig. 2C) but catalytically inactive against fluorescent-labelled
casein, indicating at least partial misfolding. Similar results were
obtained when fragilysin was expressed with the smaller Z-tag
(<10 kDa) [59], indicating that fusion proteins may have a
positive effect on target solubility without necessarily implying that
it will be well folded and active. Nevertheless, these fusion tags can
have an application in the expression of proteins with known
solubility problems that need to be temporally stabilised until an
adequate condition/solution is found [67].
Expression of proteins requiring disulfide bonds and
other posttranslational modifications. Correct folding and
stabilization requires the formation of disulfide bonds in many
proteins. These can be formed in oxidising environments as found
in the periplasmic and extracellular environment of bacteria, or in
specialised organelles of eukaryotes. B. subtilis has a large
secretory capacity, whereas in E. coli secretion is mainly limited
to the periplasm [68,69]. In P. pastoris, proteins are first driven to
the endoplasmic reticulum and, after folding, they are secreted to
the extracellular medium [70]. The pCri System includes vectors
that fuse SP specialised for protein translocation to these cellular
compartments. pCri-9 and 12 can be used with E. coli cells,
whereas pCri-16 and 18 are suitable for expression in P. pastoris
and B. subtilis, respectively. In the case of pCri-12, a disulfide-
bond isomerase C (DsbC) is coexpressed with the target protein
and provides additional support in the correct pairing of disulfide
bonds in the periplasm [50].
As a test protein, we used human CPA2, which is commonly
expressed in P. pastoris cells [71]. Unexpectedly, expression trials
indicated that the protein is produced not only in the extracellular
environment of P. pastoris but also in the cytoplasm and periplasm
of E. coli cells (Fig. 2D). In contrast, B. subtilis did not express the
protein either extracellularly or intracellularly. In all cases, the
protein was soluble and correctly processed after limited tryptic
digestion, showing activity against small substrates. However, this
is not always the case. Besides the oxidising conditions other
proteins may often participate in correct folding, including
pCri System
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oxidases, foldases, isomerases and specialised chaperones [69].
Moreover, disulfide bond formation is not the only factor in
proper protein folding and stability, and further posttranslational
modifications (e.g. glycosylation) may be required, which can be
provided by P. pastoris [70].
Another approach for disulfide bond formation exploits the
oxidising cytoplasm of thioredoxin reductase B (trxB2) and
glutathione reductase (gor2) mutant E. coli cells (Origami 2)
[34]. In contrast to the commonly used BL21 cells, Origami 2
efficiently expressed PNGase F, either with pCri-4a or 8a, soluble
and catalytically active against RNase B (Fig. 2E and 2F). The
protein contains disulfide bonds that require an oxidising
environment, which is adequately formed in the cytoplasm of
mutant cells. In addition, the combined use of thioredoxin A
(TRX) as fusion protein in pCri-4a and expression in Origami 2
can lead to the overexpression of small multi-disulfide proteins,
among others [69,72]. This system takes advantage of TRX,
which acts as an oxidant when it operates in an oxidized milieu
found in mutant cells [34], thus providing an additional
mechanism for disulfide bond formation within the cytoplasm.
TRX is subsequently removed by TEV proteinase cleavage in the
presence of selected amounts of redox agents to assist in correct
disulfide bond pairing [72,73].
Expression of membrane proteins. Membrane proteins
are among the targets most requested and at the same time
difficult to express and purify. To address this issue, a vector was
prepared, which fuses a small protein from B. subtilis with target
proteins (pCri-13a). This protein, known as the membrane-
integrating sequence for translation of integral-membrane protein
constructs (MISTIC), folds autonomously into membranes,
simultaneously dragging the tagged-protein to the cell membrane
[74]. Moreover, this vector contains a longer His8-tag in tandem
with MISTIC in order to provide higher affinity for Ni-NTA
affinity purification.
Figure 1. Vector overview of the pCri System. (A) Vectors for cytoplasmic protein expression. (B) Vectors for periplasmic and extracellular
protein expression. An N-terminal His6-tag can be fused in all vectors for intracellular expression except of pCri-7. Other tags can also be fused
including MBP, TRX, GST, SUMO, MISTIC, and LSL (Table 1–3). In all vectors, a C-terminal His6-tag or Strep-tag is attached if a stop codon is omitted
within the target gene. Black arrows indicate the proteinase (i.e. TEV, SENP1 or thrombin) and signal peptide (SP) cleavage sites. Restriction sites
allowing directional cloning are also shown. For more details regarding each vector, refer to Fig. S1.
doi:10.1371/journal.pone.0112643.g001
Table 4. Sequencing primers for the pCri System.
Primer Name Vector (pCri) Sequence site Primer sequence
T7 promoter 1-14a,b except 12a–b* 59end Universal
T7 terminator 1-14a,b except 12a–b* 39end Universal
seq-pCri-1 1a and b internal* 59end GAAATCATGCCGAACATCCC
seq-pCri-4 4a and b internal* 59end GCGGCAACCAAAGTGGGTGCAC
seq-pCri-6 6a and b internal* 59end GACCATCCTCCAACTAGTG
seq-pCri-11 11a and b internal* 59end CAAAAGAACTGGGAATG
59seq-pCri-12 12a** and b** 59end GATAACGAGGGCAAAAAATG
39seq-pCri-12 12a* and b* 39end CAAAGTAAACAACATAAAAC
seq-pCri-13 13a internal* 59end CAGATTTTATCCATCTC
seq-pCri-14 14a and b internal* 59end CTTCTGGAATCACCCTC
59 AOX1 15a,b* and 16a** 59end Universal
39 AOX1 15a,b* and 16a* 39end Universal
59seq-pCri-17 17a* and 18a** 59end CTTATCACTTGAAATTG
39seq-pCri-17 17a* and 18a* 39end GATTTTATTAGTACAGGGAC
*Hybridises before NcoI, NdeI or XhoI restriction sites.
**Hybridises before the SP.
doi:10.1371/journal.pone.0112643.t004
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Figure 2. Protein expression and purification trials using the pCri System. (A) The GFP gene was cloned into pCri-1a, 4a, 6a, 8a, 11a, and
14a, the proteins expressed in E. coli BL21 cells, and subsequently purified by Ni-NTA-affinity chromatography except for MBP, GST, and LSL fusion
products, which were purified by their respective specific affinity resins. (B) The gene coding for fragilysin was cloned into pCri-1a, 4a, 6a and 8a, and
expressed in E. coli Origami 2 cells. Total (T) and soluble (S) fractions of crude protein extracts were further analysed by SDS-PAGE. All expression trials
were performed at 20uC except for pCri-1a, which was also performed at 37uC. (C) Partially purified MBP-fragilysin before (2) and after (+) TEV
proteinase cleavage. Arrows indicate the soluble fraction of fragilysin (white) and the MBP (black) after TEV proteinase cleavage. (D) Expression of
CPA2 intracellularly (lanes 1 and 2) or periplasmatically (lanes 3 and 4) in E. coli cells, and extracellularly (lanes 5 and 6) in P. pastoris cells. Lanes
indicate samples before (1, 3 and 5) and after (2, 4 and 6) tryptic digestion. Arrows indicate the pro-CPA2 (black), the mature form (grey) and the pro-
peptide (white) after tryptic cleavage. (E) The PNGase F gene was cloned into pCri-4a and 8a and expressed overnight at 20uC in E. coli BL21 and
Origami 2 cells. Total (T) and soluble (S) fractions of crude protein extracts were further analysed by SDS-PAGE. (F) Activity of affinity-purified TRX-
PNGase F against glycosylated RNase B. (+) and (2) indicate presence and absence of PNGase F. Arrows indicate the PNGase F (black), native RNase B
(grey) and deglycosylated RNase B (white). (G) MecR1 was expressed in E. coli BL21 using pCri-8a or 13a, and soluble fractions were analysed by
Western blotting with specific antibodies as detailed in ‘‘Materials and Methods’’. A black arrow indicates the detected MecR1. (H) Partially purified
MISTIC-MecR1 after Ni-NTA-affinity purification. (I) Partially purified MBP-GFP, SUMO-GFP and MISTIC-MecR1 were digested with TEV proteinase,
pCri System
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For evaluation purposes, we cloned and expressed MecR1, a
membrane metallopeptidase from Staphylococcus aureus implicat-
ed in methicillin resistance [75]. Detectable levels of expression
were only achieved when the protein was fused with MISTIC,
whereas mere fusion with an N-terminal His6-tag was unsuccessful
(Fig. 2G). Moreover, expression yields of the protein were
sufficient (0.4 mg of affinity purified protein per litre of culture)
to enable partial purification by Ni-NTA affinity chromatography
after solubilisation of the membranes with the zwitterionic
detergent LDAO (Fig. 2H). Although further studies are required
to assess the folding state of this protein, fusion with MISTIC
allowed us to express it in milligram amounts. Many other
membrane proteins were also expressed in fusion with various
MISTIC constructs, indicating that this system could be an
alternative approach for membrane proteins that are difficult to
express [52].
Removal of fusion tags. In most cases, release of the target
protein from any fused tag is desirable. In the pCri System, a TEV
proteinase cleavage site is introduced immediately after the tag in
all vectors except for pCri-11 and pCri-13, in which a SENP1 or
thrombin site is found, respectively (Fig. S1). TEV proteinase is a
highly specific enzyme that recognises an hexapeptide sequence
[76], whereas SENP1 further offers robustness and high proteo-
lytic activity in addition to high specificity, usually requiring only
minute amounts for tag removal [77]. Moreover, use of a
thrombin cleavage site in pCri-13a was necessary due to the low
efficiency of TEV proteinase in the presence of detergents which
are required during membrane-protein solubilisation [78]. In
addition, linker sequences (Gly-Ser)5 and Gly3-Ala were intro-
duced before and after the thrombin recognition site, respectively,
to improve access for proteinase cleavage (Fig. S1) [79].
Tag removal was achieved with variable amounts of endopep-
tidases, different incubation times and temperatures (Fig. 2I).
These studies indicated that optimisation trials are needed in each
case to identify the best conditions for complete digestion (e.g.
buffer, temperature, proteinase:substrate ratio). Proteinase cleav-
age and tag removal result in the incorporation of one or two extra
residues at the N-terminus of the expressed protein except for
pCri-4b and pCri-13a, which attach three and six residues,
respectively (Tables 1–3).
Conclusions
Here we introduce a vector collection designed for large-scale
recombinant protein overexpression, and demonstrate its suitabil-
ity in a series of test proteins. The choice of a suitable expression
vector should be based on target and tag properties. The
availability of a range of fusion tags allows the choice between
different affinity purification methods. Moreover, some tags were
included for specific use, such as MISTIC and TRX, which are
intended for expression of membrane and disulfide rich proteins,
respectively. In general, our common strategy first explores the
effects of the presence or absence of N- or C- terminal tags (e.g.
His6-tag or Strep-tag) on each construct under different host cell
growth conditions. Omission of the tag or alternation of the
position can drastically influence the expression and solubility of
the protein. If this approach is ineffective the chances of optimising
the expression by testing other fusion combinations are reduced.
Several reports showed the beneficial effects of the fusions on
target solubility [2,67]. However, this is not always the case: the
protein is often dragged into solution, rather than acting as a
chaperone for the proper folding of its fusion partner. Removal of
the fusion tag can revert the positive effect and cause precipitation
[47,48]. If this occurs, then modified constructs, other homologous
targets or even other expression systems need to be explored,
including bacterial and eukaryotic cells that can be easily tested
using the vector collection of the pCri System.
Supporting Information
Figure S1 Partial nucleotide sequence and translation
of the pCri System vectors.
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